Clinical trial
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With…
NCT00039494 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039494 |
|---|---|
| Title | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors |
| Official title | A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma |
| Intervention type | Drug, Radiation |
| Interventions | erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide |
| Enrollment | 171 |
| Start date | Dec 1, 2002 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: